ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
1.11
0.5385
(94.23%)
終値: 11月22日 6:00AM
0.96
-0.15
( -13.51% )
取引時間後: 9:04AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

通貨
0.96
買値
0.95
売値
0.97
出来高
2,545,586
0.59 日の範囲 1.134
0.50 52 週間の範囲 4.95
時価総額
前日終値
0.5715
始値
0.59
最終取引時間
09:04:53
財務取引量
US$ 2,147,520
VWAP
0.843625
平均取引量 (3 か月)
16,660
発行済株式数
112,824,183
配当利回り
-
PER
2.92
1 株当たり利益 (EPS)
0.38
歳入
409.92M
純利益
42.54M

Procaps Group SA について

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardio... Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. 詳細を表示

セクター
Medicinal Chems,botanicl Pds
業界
Medicinal Chems,botanicl Pds
ウェブサイト
本社
Luxembourg City, Luxembourg, Lux
設立
-
Procaps Group SA is listed in the Medicinal Chems,botanicl Pds sector of the ナスダック市場 with ticker PROC. The last closing price for Procaps was US$0.57. Over the last year, Procaps shares have traded in a share price range of US$ 0.50 to US$ 4.95.

Procaps currently has 112,824,183 shares in issue. The market capitalisation of Procaps is US$64.48 million. Procaps has a price to earnings ratio (PE ratio) of 2.92.

PROC 最新ニュース

Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing

MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company...

Procaps Issues Shareholder Letter Update

MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical...

Procaps Issues Shareholder Letter Update

MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical...

Procaps Issues Shareholder Letter

MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical...

Procaps Group Announces New Chairman

Ruben Minski decides to step down as Executive Chairman and José Minski is appointed as new Chairman of the Board Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading...

Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F

Procaps Group (Nasdaq: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has received a letter from the Nasdaq...

Procaps Group Delays Filing of Annual Report on Form 20-F

Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has determined it is unable to file...

Procaps Group Delays Filing of Annual Report on Form 20-F

Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has determined it is unable to file...

Procaps Announces Formation of Strategic Committee to Explore Value Creation Alternatives

Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is conducting a process to explore...

Procaps Issues Shareholder Letter from New CEO

Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Jose Vieira, CEO of...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.1112.94117647060.851.28810.5494210.60261302CS
4-0.92-48.93617021281.881.990.5326091.10374165CS
12-1.03-51.75879396981.992.35010.5166601.41355229CS
26-1.95-67.01030927842.912.93990.5102441.65741152CS
52-1.48-60.65573770492.444.950.5197482.800282CS
156-9.04-90.41010.490.5213605.54807907CS
260-7.45-88.58501783598.4111.980.5266246.54952563CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
VRPXVirpax Pharmaceuticals Inc
US$ 1.129
(91.45%)
12.45M
MTEMMolecular Templates Inc
US$ 0.5626
(48.05%)
12.58M
EYENEyenovia Inc
US$ 0.1425
(35.59%)
12.54M
BENFBeneficient
US$ 1.07
(21.59%)
1.25M
REPLReplimune Group Inc
US$ 13.01
(17.74%)
301.23k
CETXCemtrex Inc
US$ 0.1424
(-27.61%)
4.03M
KSCPKnightscope Inc
US$ 15.40
(-15.80%)
42.57k
APTOAptose Biosciences Inc
US$ 0.2081
(-14.71%)
271.18k
LGTYLogility Supply Chain Solutions Inc
US$ 9.66
(-13.75%)
26.44k
PROCProcaps Group SA
US$ 0.96
(-13.51%)
533.87k
ELABElevai Labs Inc
US$ 0.02035
(0.74%)
15.74M
MTEMMolecular Templates Inc
US$ 0.5626
(48.05%)
12.58M
EYENEyenovia Inc
US$ 0.1425
(35.59%)
12.54M
VRPXVirpax Pharmaceuticals Inc
US$ 1.129
(91.45%)
12.45M
CDTConduit Pharmaceuticals Inc
US$ 0.1023
(-5.19%)
9.98M

PROC Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock